LRRC25 and in situ carcinoma: Unexpectedly, the combination of P-MAPA with CIS promoted a higher overexpression of TLR4 compared to the therapies alone (1.02- and 1.36-fold increase vs. P-MAPA and CIS groups, respectively; Table 1, Fig. 5h, i, k).